Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Fourth-Quarter 2020 Financial Results Revenues of $2.213 Billion GAAP Cash Generated from Operations of $394 Million GAAP Net Loss of $153 Million...
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") is pleased to announce that it will expand its Board of Directors...
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced the U.S....
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced it will reduce debt by $100 million through the...
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its gastroenterology (GI) business, Salix Pharmaceuticals, ("Salix"), one of the...
Bausch Health Companies Inc. (NYSE: BHC, TSX: BHC) ("Bausch Health" or the "Company") today announced that the Company will participate in three...
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") issued the following statement in response to the Schedule 13D filed...
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company"), Bausch + Lomb, a leading global eye health business, and Nicox...
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and its dermatology business, Ortho Dermatologics, one of the largest prescription...
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), and Prevent Blindness, the...
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") will release its fourth-quarter and full-year 2020 financial results on Wednesday, Feb....
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that LUMIFY®...
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that two...
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company"), and Novaliq...
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") will provide a preliminary update on its fourth-quarter and full-year ...
Bausch Health Companies Inc. (NYSE/TSX: BHC) today announced that Joseph C. Papa, chairman and chief executive officer, is scheduled to participate...
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that the Office for Registration of Medicinal Products, Medical...
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that on Dec. 31, 2020 it will pay down an additional...
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") and Bausch + Lomb, its leading global eye health business, announced...
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has priced and upsized its previously...
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") announced today that it has launched an offering of a combined $1.75...
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health") and Bausch + Lomb, its leading global eye health business, today announced the results ...
Bausch + Lomb, a leading global eye health business of Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today announced that its...
Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health" or the "Company") today announced that the Company will participate in two investor...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.